ParaPRO LLC in its US$89.5 million asset sale to Cipher Pharmaceuticals

On July 29, 2024, Cipher Pharmaceuticals Inc. announced the signing of a definitive asset purchase agreement with ParaPRO LLC (“ParaPRO”) and the closing of the acquisition of the global product rights for Natroba™ (Spinosad), as well as the commercial sales team in the United States for total consideration of US$89.5 million.

ParaPRO is a specialty pharmaceutical company focused on innovating antiparasitic formulations that minimize the disruption and economic burden on patients and families and providing support for the broader professional community with the most current insights, tools and resources that educate and inform.

Osler, Hoskin & Harcourt LLP advised ParaPRO with a team consisting of Alex Gorka, Amelia Miao, Michael Vandenberghe, Aliza Zigler (Corporate), David Davachi, Taylor Cao and Matthew Zvan (Tax).